论文信息 - Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial - 字舞流文

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

S. Lamola | M. Lal | P. Pitisuttithum | J. McLellan | A. García-Sastre | C. Hsieh | P. Palese | M. Meseck | N. Bhardwaj | F. Krammer | I. Mena | L. Mercer | V. Luvira | S. Lawpoolsri | B. Innis | F. Amanat | Steven P. Tran | Weina Sun | Yonghong Liu | S. McCroskery | S. Slamanig | P. Wirachwong | R. Scharf | R. Hjorth | R. Raghunandan | S. Khan | S. Muangnoicharoen | W. Phumratanaprapin | C. Sivakorn | J. M. Carreño | B. Phonrat | N. Suthepakul | S. Surichan | S. Kamolratanakul | J. Tcheou | L. Gagnon | J. White | S. Puksuriwong | Y. Sabmee | S. Theerasurakarn | R. Kaweepornpoj | K. Poopipatpol | P. Narakorn | S. Prangpratanporn | R. Singchareon | N. Thantamnu | Thanakrit Vilasmongkolchai | S. Khan | S. Mccroskery | Sant Muangnoicharoen | Supitcha Kamolratanakul | Sumalee Prangpratanporn | Steve Lamola | Ruangchai Kaweepornpoj | Stephen McCroskery | Yupa Sabmee | Ratsamikorn Singchareon | Nava Suthepakul | Narumon Thantamnu | Kittisak Poopipatpol | Sompone Theerasurakarn | Manjari Lal

[1] A. García-Sastre,et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses , 2021, Nature Communications.

[2] H. van Bakel,et al. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients , 2021, EBioMedicine.

[3] Lindsay N. Carpp,et al. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial , 2021, medRxiv.

[4] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[5] A. Iafrate,et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[6] M. Carroll,et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays , 2021, Nature Protocols.

[7] D. Montefiori,et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 , 2021, The New England journal of medicine.

[8] K. Makar,et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.

[9] J. Wrammert,et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant , 2021, Cell Host & Microbe.

[10] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[11] A. Godzik,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[12] J. Wood,et al. Global production capacity of seasonal and pandemic influenza vaccines in 2019 , 2020, Vaccine.

[13] M. Brindley,et al. SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus , 2020, Viruses.

[14] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.

[15] R. Baric,et al. A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine , 2020, bioRxiv.

[16] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[17] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[18] John D Campbell,et al. Development of the CpG Adjuvant 1018: A Case Study. , 2017, Methods in molecular biology.